Active Ingredient(s):Boceprevir FDA Approved: * May 13, 2011 Pharm Company: *SCHERING Category:Hepatitis
Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. It binds to the HCV nonstructural protein 3 active site.
It was initially developed by Schering-Plough, then by Merck after it acquired Schering in 2009. It was approved by the FDA in May 2011. In January 2015, Merck announced that they would be voluntarily withdrawing...
* May have multiple approval dates, manufacturers, or labelers. 4 Discussions